clinical development
[용어속성] Term
Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?
Pharmacology
[키워드] activate
acute respiratory syndrome
adaptive
Anti-viral
Antiviral
Antiviral compound
antiviral drug
approach
approaches
approved drug
benefit
cause
chaperone
clinical development
clinical trials
coronavirus
Course
COVID-19
COVID-19 pandemic
COVID-19 patients
CoVs
Drug repurposing
drugs
Endoplasmic reticulum
ER membranes
ER stress
expected
facilitate
Health
host cell
host cell response
host protein
identify
in vitro
Infection
infections
interact
Interaction
interfere
Intervention
Ligand
mechanism
Medicine
membrane-bound
modulation
occur
pathway
patients
potential mechanism
Prevent
professional
protective immune response
Proteins
provide
receptor
reduce
regulate
Repurposed drugs
repurposing
SARS-CoV-2
SARS-CoV-2 protein
sigma-1 receptor
Stress
targeting
the disease
therapeutic
therapy
treat
unique
upstream
viral replication
[DOI] 10.3389/fphar.2020.582310 PMC 바로가기 [Article Type] Pharmacology
[DOI] 10.3389/fphar.2020.582310 PMC 바로가기 [Article Type] Pharmacology
Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019
코로나바이러스 2019에 렘데시비르를 사용한 간 장애
Multicenter Study
Published on
Journal: Clinical gastroenterology and hepatology : the off [Category] Coronavirus, SARS, 비임상,
Journal: Clinical gastroenterology and hepatology : the off [Category] Coronavirus, SARS, 비임상,
[키워드] Adverse drug reaction
adverse event
adverse events
Aminotransferase
antiviral activity
available data
Bilirubin
breath
broad spectrum
Cell culture
cell cultures
clinical development
clinical trials
Cohort studies
cohort study
compassionate-use
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patients
disorder
double-blind
drug
drug reaction
Drug-induced liver injury
elevated
EMA
European Medicines Agency
FDA
food
healthy volunteer
healthy volunteers
hepatic
hepatic enzyme
hepatic enzymes
hepatotoxicity
hospital
human coronavirus
increase
Infection
Intravenous remdesivir
investigator
investigators
Liver injury
mouse model
Mouse models
nucleotide
Patient
patients hospitalized
patients with COVID-19
Placebo
placebo recipient
placebo recipients
placebo-controlled clinical trial
proportion
raised
Randomized
recipient
Remdesivir
reported
respiratory
safety profile
Severe acute respiratory syndrome
Severe Acute Respiratory Syndrome-associated Coronavirus 2
severe coronavirus disease
severe COVID-19
treated
Treatment
[DOI] 10.1016/j.cgh.2020.07.050 PMC 바로가기 [Article Type] Multicenter Study
[DOI] 10.1016/j.cgh.2020.07.050 PMC 바로가기 [Article Type] Multicenter Study
A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury
뮤신-1 감소 화합물에 대한 고함량 선별 검사를 통해 포스타마티닙을 급성 폐 손상의 신속한 용도 변경 후보로 확인
Article
[키워드] acute lung injury
acute respiratory distress
acute respiratory distress syndrome
ALI
approved
ARDS
breath
candidate
Cell
cell surface
clinical development
clinical outcomes
Compound
COVID-19
drug
drug candidate
Drug repurposing
epithelial cells
fostamatinib
fostamatinib.
identify
Immune thrombocytopenia
inhibitor
lung
lung epithelial cell
Lung epithelial cells
Lung injury
metabolite
mouse model
MUC1
mucin
pandemic
pandemic spread
Potential treatment
potential treatments
predict
promote
Protein
R788
Rapid
reduce
repurposing
respiratory distress
Respiratory distress syndrome
SARS-CoV-2
Screen
spleen
Spread
Stage
SYK
syndrome
the cell
thrombocytopenia
Treatment
tyrosine
[DOI] 10.1016/j.xcrm.2020.100137 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.xcrm.2020.100137 PMC 바로가기 [Article Type] Article
An aberrant STAT pathway is central to COVID-19
Reviews
[키워드] activate
Activation
affected
age
approved drugs
ARDS
Autopsy
bind
cardiovascular diseases
cascade
catastrophic
caused
characterized
chemokines
clinical development
Clinical symptoms
Coagulopathy
component
COVID-19
DAD
diabetes
Diffuse alveolar damage
drug
dysfunction
EGFR
Endothelial cell
ENhance
function
Hyperactivation
hypertension
hypoxic environment
IFN-I
induce
Infection
inhibit
initiated
innate immune cell
interferon
lung
Lung injury
macrophages
nsp1
obesity
ORF6
pathophysiology
pathway
Perspective
Phosphorylation
positive feedback loop
Proinflammatory cytokine
Proteins
recruitment
risk factor
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2-infected cells
secretion
Severe case
Signaling
STAT
Stat1
STAT3
stimulate
subsequent
TLR4
Transcription
treat
Treatment
Type
upregulation
widespread
[DOI] 10.1038/s41418-020-00633-7 [Article Type] Reviews
[DOI] 10.1038/s41418-020-00633-7 [Article Type] Reviews
Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics
Review article
[키워드] accelerate
accelerated
Anticoagulants
antivirals
approved
clinical development
clinical testing
collected
Compound
COVID-19
development
Drug discovery
immunomodulators
Pandemics
path
Preclinical
Rapid
required
SARS-CoV-2
skewed
Support
therapeutic agent
Therapeutics
Trial
Vaccine
[DOI] 10.1016/j.chom.2020.09.017 [Article Type] Review article
[DOI] 10.1016/j.chom.2020.09.017 [Article Type] Review article
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Reviews
[키워드] acute respiratory syndrome
ADE
anti-SARS-CoV-2 antibody
Antibody-dependent enhancement
clinical development
coronavirus
COVID-19
dengue virus
drug
evaluate
exacerbate
mechanism
other respiratory virus
respiratory syncytial virus
resulting
risk
SARS-CoV
SARS-CoV-2
SARS-CoV-2 vaccine
therapy
trials
Vaccine
[DOI] 10.1038/s41564-020-00789-5 [Article Type] Reviews
[DOI] 10.1038/s41564-020-00789-5 [Article Type] Reviews
Soluble ligands as drug targets
Reviews
[키워드] antibody-based therapy
approved
Autoimmune disorders
Cancer
Characteristics
clinical development
Clinical studies
clinically
cytokine
disease
Diseases
drug
drug target
drugs targeting
Enzymes
FDA
growth factor
identify
increasingly
indication
Inflammation
Inflammatory cytokine
Ligand
ligands
pathway
predominant
Protein
reached
receptors
review
target
targets
tested
therapeutic
unique
[DOI] 10.1038/s41573-020-0078-4 [Article Type] Reviews
[DOI] 10.1038/s41573-020-0078-4 [Article Type] Reviews
Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns
Other
[키워드] accelerated
Area
clinical development
coronavirus
coronavirus vaccine
Coronaviruses
COVID-19
COVID-19 pandemic
disease
disease enhancement
drastic
effective
Epidemic
Evidence
expert
identify
in vivo
individual
infectious disease outbreak
Influenza
knowledge
measure
MERS-CoV
Protecting
risk
Safe
SARS-CoV
SARS-CoV-2
Spanish
Spread
tested
theoretical risk
vaccinated individual
vaccination
Vaccine
vaccine candidate
vaccine candidates
vaccine safety
while
[DOI] 10.1080/14760584.2020.1800463 PMC 바로가기 [Article Type] Other
[DOI] 10.1080/14760584.2020.1800463 PMC 바로가기 [Article Type] Other
Psychedelic science in post-COVID-19 psychiatry
Editorial
[키워드] clinical development
consequence
coronavirus
COVID-19
Depression
determine
disorder
double-blind trial
early stage
Efficacy
Efficacy and safety
Imperial College London
implication
increase in
inhibitor
mechanism
medium
mental health burden
mental health problem
mitigate
obsessive compulsive
offer
optimal dose
predicted
preliminary evidence
psilocybin
psychedelic
psychedelics
psychiatric disorder
psychiatry
Psychological
question
Result
selective
Selective serotonin reuptake inhibitors
Serotonin
therapeutic
therapy
TRD
Treatment
Treatment-resistant depression
while
[DOI] 10.1017/ipm.2020.94 PMC 바로가기 [Article Type] Editorial
[DOI] 10.1017/ipm.2020.94 PMC 바로가기 [Article Type] Editorial